Main Menu

The technology described is a sophisticated and high-throughput luciferase immunoprecipitation system (LIPS) assay designed to detect antibodies specific to Varicella-zoster virus (VZV) glycoprotein E (gE). By transfecting cells with VZV protein-Renilla luciferase fusion protein constructs and subsequently performing immunoprecipitations with protein A/G beads, this innovative assay enables the quantitative measurement of VZV gE antibody levels in blood serum samples.

This technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram, respectively, these antibodies have the potential to offer enhanced protection against rabies when administered alongside rabies vaccines.

Bundibugyo virus (BDBV) is one of several ebolaviruses that cause Ebola virus disease (EVD). Sporadic outbreaks continue to occur in Central Africa, highlighting the need for effective vaccines that provide rapid protection.

The technology described involves a groundbreaking method for treating intracellular pathogen infections by targeting CD47, a widely expressed transmembrane glycoprotein that acts as a ligand for phagocytic receptors. By administering agents that inhibit CD47 binding to these receptors, the approach enhances the phagocytic removal of infected cells, leading to increased clearance of intracellular pathogens.

Novel Engineered RBD Antigens: Elevating Coronavirus Vaccine Efficiency and Efficacy. These groundbreaking antigens, derived from the spike protein's receptor-binding domain, are meticulously designed through a computational pipeline, resulting in superior attributes. They increase protein yield sevenfold, ensuring efficient large-scale manufacturing. With elevated thermal stability and a tenfold boost in antibody production, these antigens present a significant stride towards potent and globally accessible coronavirus vaccines.

This technology involves the creation of monoclonal antibodies through hybridoma technology, specifically, hybridomas 3B6, 14B7, 2D3, 2G4, 1G3, 6H3, 6C5, and 3D12, which exhibit a high degree of reactivity with Bacillus anthracis protective antigen (PA). These monoclonal antibodies have shown great promise in the field of anthrax detection and diagnosis. Their exceptional specificity for Bacillus anthracis PA suggests their potential application in diagnostic devices.

This technology involves the development of lgG1 Fe variants designed to interact more effectively with the neonatal Fc receptor (FcRn) in a pH-dependent manner. By enhancing this interaction, these variants extend the serum half-life of therapeutic antibodies, reducing the need for frequent administration. This breakthrough holds the potential to make therapeutic antibody treatments more convenient, cost-effective, and accessible for a wide range of diseases.

Monoclonal antibodies produced by hybridomas IE5, IE9, and 13B3 are specific for the Bacillus anthracis PA20 fragment. These antibodies hold significant potential for rapid and precise Bacillus anthracis diagnosis in clinical and environmental samples. They can be employed in various diagnostic assays, offering a valuable tool for public health and biosecurity applications. Rigorous testing and validation are essential before their integration into diagnostic devices.

The Vaccine Research Center has engineered two monoclonal antibodies, N6 and VRC07-523LS, as new contenders in the fight against HIV-1. These antibodies are designed to target the virus more effectively by removing certain glycans and modifying amino acids to enhance their neutralizing capability and reduce the risk of autoimmunity. The technology holds promise for improved HIV-1 treatments and may offer broader protection due to its potential coverage of various viral variants.

Trispecific and trivalent binding proteins represent a breakthrough in the battle against HIV infection. These specialized proteins are engineered with four polypeptide chains forming three antigen binding sites, enabling precise targeting of HIV target proteins. Addressing the formidable challenges of HIV treatment, including the virus's high mutation rate and the persistence of viral reservoirs, these binding proteins offer a potential solution to breakthrough infections.